Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released Aug 12, 2024, before the open
10-Q filed Aug 12, 2024, 43 days after period end · 0001628280-24-036591
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $643.00K | $1.03M | $3.36M |
| Net Income | $98.46M | -$8.19M | -$12.99M | -$17.11M |
| EPS Diluted |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| -$14.07 |
| -$140.73 |
| -$1.38 |
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.